Emerging and Evolving Concepts in Cancer Immunotherapy Imaging

Archive ouverte

Dercle, Laurent | Sun, Shawn | Seban, Romain-David | Mekki, Ahmed | Sun, Roger | Tselikas, Lambros | Hans, Sophie | Bernard-Tessier, Alice | Mihoubi Bouvier, Fadila | Aide, Nicolas | Vercellino, Laetitia | Rivas, Alexia | Girard, Antoine | Mokrane, Fatima-Zohra | Manson, Guillaume | Houot, Roch | Lopci, Egesta | Yeh, Randy | Ammari, Samy | Schwartz, Lawrence

Edité par CCSD ; Radiological Society of North America -

International audience. Criteria based on measurements of lesion diameter at CT have guided treatment with historical therapies due to the strong association between tumor size and survival. Clinical experience with immune checkpoint modulators shows that editing immune system function can be effective in various solid tumors. Equally, novel immune-related phenomena accompany this novel therapeutic paradigm. These effects of immunotherapy challenge the association of tumor size with response or progression and include risks and adverse events that present new demands for imaging to guide treatment decisions. Emerging and evolving approaches to immunotherapy highlight further key issues for imaging evaluation, such as dissociated response following local administration of immune checkpoint modulators, pseudoprogression due to immune infiltration in the tumor environment, and premature death due to hyperprogression. Research that may offer tools for radiologists to meet these challenges is reviewed. Different modalities are discussed, including immuno-PET, as well as new applications of CT, MRI, and fluorodeoxyglucose PET, such as radiomics and imaging of hematopoietic tissues or anthropometric characteristics. Multilevel integration of imaging and other biomarkers may improve clinical guidance for immunotherapies and provide theranostic opportunities.

Consulter en ligne

Suggestions

Du même auteur

Early F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab

Archive ouverte | Chen, Aiping | CCSD

International audience. Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, are associated with high response rates in patients with relapsed or refractory class...

Interpretation of 2-[F-18]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors

Archive ouverte | Manson, Guillaume | CCSD

International audience. The development of immunotherapy has revolutionized cancer treatment, improving the outcome and survival of many patients. Immune checkpoint inhibitors (ICIs), the most common form of immunot...

Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy

Archive ouverte | Dercle, Laurent | CCSD

International audience. Immunotherapy offers the potential for durable clinical benefit but calls into question the association between tumor size and outcome that currently forms the basis for imaging-guided treatm...

Chargement des enrichissements...